Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Common Variable Immunodeficiency 1Agammaglobulinemia 1

Interventions

Specimen Handling 327Magnetic Resonance Spectroscopy 278pembrolizumab 268Carboplatin 190Cyclophosphamide 187Biopsy 183Cisplatin 163Gemcitabine 138Paclitaxel 137Bevacizumab 124fludarabine 122Nivolumab 119Radiotherapy 116Oxaliplatin 94venetoclax 92Docetaxel 90Fluorouracil 89Capecitabine 89Dexamethasone 86Drug Therapy 77Pemetrexed 75Rituximab 74Leucovorin 72durvalumab 71Blood Specimen Collection 70Radiosurgery 69Standard of Care 68atezolizumab 67Doxorubicin 66Radiation 63

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Hizentra × 90 days × Clear all
NCT07582432 2026-05-12

SIGMA

Grifols Biologicals, LLC

Phase 3 Recruiting
49 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
100 enrolled
Plasma cell

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡